ORIC reports 84% tumor response in Phase 1b
- ORIC Pharmaceuticals reported Phase 1b enozertinib data showing an 84% investigator-assessed tumor response rate in previously untreated lung cancer patients with atypical EGFR mutations.
- Independent reviewers confirmed an 80% systemic response rate, while six-month progression-free survival reached 88% in the early-stage trial.
- ORIC plans to initiate its global Redwood-1 Phase 3 trial in the first half of 2027, enrolling approximately 360 patients to compare enozertinib against existing treatments.
ORIC Pharmaceuticals (NASDAQ:ORIC) reported Phase 1b enozertinib results showing an 84% confirmed tumor response rate in previously untreated lung cancer patients.
Independent reviewers confirmed an 80% response rate, while the September 4 dataset included 26 patients, with 65% having brain metastases.
Intracranial response rates reached 70% by investigators and 67% by independent review, while six-month progression-free survival was 88%.
Grade 3 treatment-related adverse events affected 23% of patients, with no resulting discontinuations, although median progression-free survival and response duration remained immature.
ORIC expects to initiate its global Redwood-1 Phase 3 trial in the first half of 2027, enrolling approximately 360 patients.
The planned study will compare enozertinib against physician-selected osimertinib or afatinib in patients with non-small cell lung cancer harboring atypical EGFR mutations.
ORIC previously selected an 80 mg daily enozertinib dose for potential Phase 3 development and continues evaluating the drug across EGFR-mutated lung cancer populations.
